Camoteskimab for Atopic Dermatitis
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.
Are You a Good Fit for This Trial?
This trial is for adults aged 18-65 with moderate-to-severe atopic dermatitis (eczema) affecting at least 10% of their skin, who have had the condition for over a year and haven't improved enough with creams or ointments. Participants must be able to use contraception and give consent.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are randomized to receive either camoteskimab or placebo for 24 weeks
Extension
All participants receive camoteskimab in the extension period
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Camoteskimab
Trial Overview
The study compares camoteskimab, an experimental drug, to a placebo in people with moderate-to-severe eczema. It is randomized and double-blind, meaning neither patients nor doctors know who gets which treatment.
How Is the Trial Designed?
4
Treatment groups
Experimental Treatment
Placebo Group
Camoteskimab
Camoteskimab
Camoteskimab
Dummy version of the study drug
Find a Clinic Near You
Who Is Running the Clinical Trial?
Apollo Therapeutics Ltd
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.